Cancer risk and related mortality significantly higher among patients with kidney disease

Patients with kidney disease may have an increased risk of cancer and may be more likely to die from cancer. Researchers used healthcare databases in Ontario, Canada, to categorize patients according to their kidney function (using blood test data) or records that identify patients receiving dialysis or patients with kidney transplants.

They then looked at the patients' risk of being diagnosed with cancer and of dying of cancer. Patients with mild to moderate kidney disease and kidney transplant recipients had a higher risk of cancer than patients with normal kidney function. Patients with kidney disease had a higher risk of dying from cancer than patients with normal kidney function, particularly from cancers such as bladder, kidney, and multiple myeloma.

This study, published in the American Journal of Kidney Diseases (AJKD), suggests that improved strategies to detect and treat cancer in patients with kidney disease are needed.

Source:
Journal reference:

Kitchlu, A., et al. (2022) Cancer Risk and Mortality in Patients With Kidney Disease: A Population-Based Cohort Study. American Journal of Kidney Diseases. doi.org/10.1053/j.ajkd.2022.02.020.

Comments

The opinions expressed here are the views of the writer and do not necessarily reflect the views and opinions of News Medical.
Post a new comment
Post

While we only use edited and approved content for Azthena answers, it may on occasions provide incorrect responses. Please confirm any data provided with the related suppliers or authors. We do not provide medical advice, if you search for medical information you must always consult a medical professional before acting on any information provided.

Your questions, but not your email details will be shared with OpenAI and retained for 30 days in accordance with their privacy principles.

Please do not ask questions that use sensitive or confidential information.

Read the full Terms & Conditions.

You might also like...
Engineered SNIPRs transform CAR T-cell precision for safer cancer therapy